Medicare Now Covers GLP-1s for Weight Loss — What the New $50 Bridge Program Means
For the first time, Medicare is helping pay for weight-loss medication prescribed purely for obesity. On July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge — a temporary demonstration program giving eligible Part D beneficiaries access to certain GLP-1 medications, including Wegovy and Zepbound, at a $50 monthly copay. The program runs through December 31, 2027, and marks a genuine policy shift: federal law has long excluded weight-loss drugs from Part D coverage, limiting GLP-1 coverage to diagnoses like diabetes and cardiovascular disease.
Why it matters.
Out-of-pocket costs have been the barrier keeping GLP-1 therapy out of reach for many older adults — commonly around $350 a month even after recent manufacturer price cuts. A $50 copay changes the arithmetic for eligible beneficiaries, and physicians expect a wave of new patients beginning treatment in the second half of 2026.
The caveats.
The Bridge is a pilot, not a law change — coverage is guaranteed only through the end of 2027, after which patients could lose it unless the program is extended or Congress acts. That timing question matters medically: GLP-1 therapy is long-term treatment, and starting a medication that may lose coverage in 18 months requires a plan. Eligibility runs through specific Part D plan participation, and clinical criteria still apply.
The physician's view.
Member physician quote pending — invite 2–3 sentences on what patients starting GLP-1s later in life should know: screening, muscle preservation, realistic expectations, and planning for the program's end-date.
For older adults considering the program, the guidance physicians give every GLP-1 candidate applies doubly: this is medically supervised therapy, not a subscription — begin with a full screening, understand the side-effect profile, protect muscle mass during rapid loss, and build the exit plan on day one.
Related on Haute MD
Articles are independently produced by the Haute Living editorial team. Featured physicians are members of the Haute MD Network — inclusion does not influence editorial coverage or rankings.